Description |
1 online resource (xiii, 460 pages) : illustrations (some color) |
Series |
Cancer drug discovery and development |
|
Cancer drug discovery and development.
|
Contents |
Mechanism of action of topoisomerase I poisons / Leroy F. Liu and Shyamal D. Desai -- Crystallographic insight into the mechanism of drug-induced topoisomerase I DNA damage / Alex B. Burgin, Jr., Bart L. Staker, and Lance Stewart -- Inhibitors of topoisomerase I function / Sidney M. Hecht -- Cytotoxic mechanisms of the topoisomerase I inhibitors / Yves Pommier [and others] -- Biochemical and genetic analyses of DNA topoisomerase I-mediated DNA damage / Robert C.A.M. Van Waardenburg and Mary-Ann Bjornsti -- Preclinical models for evaluating topoisomerase-I targeted drugs / Aarti S. Juvekar [and others] -- Mechanisms of resistance to camptothecins / Zeshaan A. Rasheed and Eric H. Rubin -- Recent advances in camptothecin drug design and delivery strategies / Thomas G. Burke [and others] -- Clinical experience with 9-aminocamptothecin: lessons for new drug development / Chris H. Takimoto -- Clinical studies of rubitecan (9-nitro 20(s) camptothecin) / Hilary Hewes, Judith A. Smith, and Claire Verschraegen -- Irinotecan: current clinical status and pharmacological aspects / Laurent P. Rivory -- Clinical experience with topotecan / Aimee K. Bence and Val R. Adams -- The clinical development of lurtotecan: experience with water-soluble and liposomal forms / Keith T. Flaherty [and others] -- Preclinical and clinical development of dx-8951f (exatecan mesylate): a hexacyclic camptothecin analog / Eric K. Rowinsky -- Camptothecins in the treatment of primary brain tumors / Clinton F. Stewart, Markos Leggas, and Henry S. Friedman -- Camptothecins in the treatment of lung cancer / Pankaj Kumar [and others] -- Use of camptothecins in the treatment of leukemia and related disorders / Bejamin M.F. Mow and Scott H. Kaufmann |
Summary |
This is a critical review of our current understanding of camptothecins, their shortcomings, and of the possibilities for improving their clinical performance. The authors discuss new camptothecin analog development, drug delivery issues for optimizing their anticancer activity, and their potential use in a variety of different cancers. Additional chapters describe what is known about the biochemistry, the pharmacology, and the chemistry of the camptothecins, including the mechanism of topoisomerase and how camptothecins poison this enzyme, the use of animal models in defining the anticancer p |
Bibliography |
Includes bibliographical references and index |
Notes |
English |
|
Print version record |
In |
Springer e-books |
Subject |
Camptothecin.
|
|
Cancer -- Chemotherapy.
|
|
Camptothecin -- therapeutic use
|
|
Neoplasms -- drug therapy
|
|
Antineoplastic Agents, Phytogenic -- therapeutic use
|
|
Camptothecin -- analogs & derivatives
|
|
Camptothecin -- pharmacology
|
|
Camptothecin
|
|
MEDICAL -- Oncology.
|
|
HEALTH & FITNESS -- Diseases -- Cancer.
|
|
Cancer -- Chemotherapy.
|
|
Camptothecin -- therapeutic use.
|
|
Neoplasms -- drug therapy.
|
|
Antineoplastic Agents, Phytogenic -- therapeutic use.
|
|
Camptothecin -- analogs & derivatives.
|
|
Camptothecin -- pharmacology.
|
|
Camptothecin.
|
|
Camptothecin
|
|
Cancer -- Chemotherapy
|
Form |
Electronic book
|
Author |
Burke, Thomas G., PhD.
|
|
Adams, Val R
|
LC no. |
2004013542 |
ISBN |
9781592598663 |
|
1592598668 |
|
1588290271 |
|
9781588290274 |
|